Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT07345572Recruiting
Early time-restricted eating for mild asthma
This study explores whether eating only during certain hours of the day (early time-restricted eating) can improve health and quality of life for adults with mild controlled asthma, compared to adults without asthma. Participants will follow a specific eating schedule for a period, and researchers will monitor outcomes.
Leicester, EnglandAges 18–65 - NCT07762872Recruiting
Satralizumab during early NMOSD attacks
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT07761026Recruiting
Living with myasthenia gravis: share your experience
This 10-year study collects information from people with myasthenia gravis to learn more about the condition and improve care. By sharing your experiences, you can help researchers understand what daily life is like and shape future treatments.
Framingham, MassachusettsAges 18 years+ - NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
Rochester, MinnesotaAges 18–60 - NCT03911128Recruiting
Treatment protocol for newly diagnosed childhood and young adult ALL
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
AalborgAges birth–45 years - NCT07556159Recruiting
Asthma Disease Patterns and Outcomes in Everyday Care
This study observes how asthma is managed and controlled in routine clinical practice. Researchers will collect information about your asthma symptoms, treatments, and outcomes over time to better understand real-world asthma management.
Chandler, ArizonaAges 6 years+ - NCT07427251RecruitingPhase 4
Study to avoid low blood sugar after meals
This trial tests if a quick-acting glucagon nasal spray can prevent low blood sugar after meals in people with type 1 diabetes who use an automated insulin pump. If you count carbs and use NovoRapid or Fiasp insulin, this could help you avoid post-meal lows.
HerlevAges 18 years+ - NCT07469592Recruiting
Mindfulness and music therapy for stem cell transplant patients
This trial tests a combined mindfulness and music therapy program delivered through an app or website. It aims to help patients cope with the stress of stem cell transplant for blood cancers like leukemia or lymphoma.
Miami, FloridaAges 18 years+ - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT06762431RecruitingPhase 1/Phase 2
CAR T-cell therapy plus lenalidomide for CLL
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Vitebsk, Select A StateAges 18 years+ - NCT06307665RecruitingPhase 3
Asthma study for teens comparing two inhalers
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
Anchorage, AlaskaAges 12–17 - NCT07560618RecruitingPhase 4
Testing a new cream for itch relief in atopic dermatitis
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Sacramento, CaliforniaAges 12 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06191315Enrolling by invitationPhase 3
Dupilumab for asthma and wheezing in young children
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Phoenix, ArizonaAges 2–5 - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT07399665Recruiting
Tezepelumab for chronic sinusitis with nasal polyps in Russia
This study tracks how well tezepelumab works for people with chronic sinusitis and nasal polyps in real-world settings. It aims to see if this medication reduces symptoms and the need for surgery.
Kazan'Ages 18 years+ - NCT07265258RecruitingPhase 4
Teprotumumab for active thyroid eye disease
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT07143669Recruiting
Screening study for mast cell disease with KIT mutation
This study looks for a specific gene change (KIT D816V) in people with certain allergic reactions or related conditions. It aims to find those who might benefit from future treatments targeting this mutation.
Birmingham, AlabamaAges 18 years+ - NCT06630104Recruiting
Studying blood cell changes after CAR-T therapy for blood cancers
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Scottsdale, ArizonaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.